Marinus Pharmaceuticals (NASDAQ:MRNS) Earns “Neutral” Rating from HC Wainwright

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “neutral” rating reaffirmed by analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $2.00 price objective on the biopharmaceutical company’s stock.

Several other research analysts have also issued reports on the stock. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. StockNews.com began coverage on Marinus Pharmaceuticals in a research report on Sunday, November 10th. They issued a “hold” rating on the stock. EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Finally, Cantor Fitzgerald lowered their price objective on Marinus Pharmaceuticals from $13.00 to $4.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Nine analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ:MRNS opened at $0.30 on Thursday. The firm has a market capitalization of $16.66 million, a P/E ratio of -0.12 and a beta of 1.26. The stock has a 50 day moving average price of $1.24 and a 200-day moving average price of $1.32. Marinus Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.02. The company had revenue of $8.54 million for the quarter, compared to analysts’ expectations of $8.95 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 446.48%. On average, equities analysts forecast that Marinus Pharmaceuticals will post -1.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Hussman Strategic Advisors Inc. grew its stake in shares of Marinus Pharmaceuticals by 14.3% in the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 10,500 shares during the period. AQR Capital Management LLC increased its position in Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 12,934 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in Marinus Pharmaceuticals in the 2nd quarter worth $28,000. SG Americas Securities LLC purchased a new position in Marinus Pharmaceuticals during the second quarter valued at $34,000. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Marinus Pharmaceuticals during the 1st quarter valued at approximately $384,000. 98.80% of the stock is owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.